New issues for copper-64: from precursor to innovative PET tracers in clinical oncology.

Laura Evangelista, Mansi Luigi, Giuseppe Lucio Cascini

Research output: Contribution to journalArticle

Abstract

The role of copper in the metabolism of human cancer cells has been largely investigated in the last 20 years and a strong relationship between copper levels and cancer progression has been demonstrated. Moreover copper is involved in tumor angiogenesis as well as in non-neoplastic conditions like neurodegenerative diseases. The main mechanism of action is related to a cellular transporter (CTR1) that plays a pivotal role in preserving the intra-cellular homeostasis, allowing at the same time the anti- tumor activity of platinum based therapies. Copper-64, emitting positrons and β- radiations, is suitable for the labeling of a large number of molecules that could be used for radionuclide imaging, being also usable in radionuclide therapy. Nevertheless few data are at present available on radiotracers labeled with radiocopper and in particular on the use of (64)Cu-Cl2 in cancer patients. In this paper we analyze the potential applications for Copper-64 as PET agent in the clinical oncological scenario.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalCurrent Radiopharmaceuticals
Volume6
Issue number3
Publication statusPublished - Sep 2013

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Fingerprint Dive into the research topics of 'New issues for copper-64: from precursor to innovative PET tracers in clinical oncology.'. Together they form a unique fingerprint.

Cite this